Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Enliven Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +7 vs. Q2 2021
- Shares held
- 15.3M
- +4.39M (+40.2%) vs. Q2 2021
- Total value
- $62.5M
- −$23.8M (−27.6%) vs. Q2 2021
- New holders
- 17
- 11 more added
- Sold out
- 10
- 8 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 214 | $4.06B |
| Q1 2026 | 171 | $2.43B |
| Q4 2025 | 126 | $960.9M |
| Q3 2025 | 134 | $1.22B |
| Q2 2025 | 125 | $1.19B |
| Q1 2025 | 122 | $983.9M |
| Q4 2024 | 114 | $1.12B |
| Q3 2024 | 102 | $1.22B |
| Q2 2024 | 93 | $1.13B |
| Q1 2024 | 74 | $780.8M |
| Q4 2023 | 62 | $539.8M |
| Q3 2023 | 61 | $533.8M |
| Q2 2023 | 63 | $797.9M |
| Q1 2023 | 45 | $735.0M |
| Q4 2022 | 36 | $74.7M |
| Q3 2022 | 31 | $18.8M |
| Q2 2022 | 26 | $13.1M |
| Q1 2022 | 31 | $26.2M |
| Q4 2021 | 35 | $33.6M |
| Q3 2021 | 38 | $62.5M |
| Q2 2021 | 31 | $86.3M |
| Q1 2021 | 40 | $92.9M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Enliven Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deutsche Bank AG | 100 | $0 | 0.00% | −21,403−99.5% | Reduced |
| Royal Bank of Canada | 32 | $0 | 0.00% | −1,962−98.4% | Reduced |
| Wells Fargo & Company | 78 | $0 | 0.00% | +48+160.0% | Added |
| Federated Hermes, Inc. | 1,676 | $7.00K | 0.00% | +1,676 | New |
| Tower Research Capital LLC (TRC) | 2,116 | $9.00K | 0.00% | +2,110+35,166.7% | Added |
| JPMorgan Chase & Co | 8,148 | $33.0K | 0.00% | −1,943−19.3% | Reduced |
| Bank of America Corp | 9,359 | $38.0K | 0.00% | −6,279−40.2% | Reduced |
| Susquehanna International Group, LLP | 11,349 | $46.0K | 0.00% | +11,349 | New |
| Advisory Services Network, LLC | 11,680 | $48.0K | 0.00% | −1,000−7.9% | Reduced |
| Cubist Systematic Strategies, LLC | 11,983 | $49.0K | 0.00% | +11,983 | New |
| Northern Trust Corp | 15,314 | $62.0K | 0.00% | +15,314 | New |
| Occudo Quantitative Strategies LP | 18,422 | $75.0K | 0.01% | +7,926+75.5% | Added |
| Bank of New York Mellon Corp | 18,661 | $76.0K | 0.00% | +18,661 | New |
| Trexquant Investment LP | 19,646 | $80.0K | 0.01% | +19,646 | New |
| State Street Corp | 21,198 | $86.0K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 23,199 | $94.0K | 0.00% | +1,284+5.9% | Added |
| Great Valley Advisor Group, Inc. | 27,411 | $112.0K | 0.01% | −4,800−14.9% | Reduced |
| Goldman Sachs Group Inc | 37,962 | $155.0K | 0.00% | +27,416+260.0% | Added |
| Walleye Trading LLC | 43,233 | $176.0K | 0.00% | +43,233 | New |
| Tudor Investment Corp Et Al | 51,923 | $212.0K | 0.00% | +51,923 | New |
| Geode Capital Management, LLC | 54,777 | $223.0K | 0.00% | +3,304+6.4% | Added |
| D. E. Shaw & Co., Inc. | 61,991 | $253.0K | 0.00% | +61,991 | New |
| BlackRock Inc. | 103,095 | $420.0K | 0.00% | +25,421+32.7% | Added |
| Millennium Management LLC | 103,803 | $424.0K | 0.00% | +68,940+197.7% | Added |
| Bridgeway Capital Management, LLC | 125,200 | $511.0K | 0.01% | +125,200 | New |
| Woodline Partners LP | 134,164 | $547.0K | 0.01% | +134,164 | New |
| Walleye Capital LLC | 167,657 | $684.0K | 0.02% | +167,657 | New |
| Two Sigma Investments, LP | 249,495 | $1.02M | 0.00% | +249,495 | New |
| Two Sigma Advisers, LP | 260,600 | $1.06M | 0.00% | +260,600 | New |
| Renaissance Technologies LLC | 274,300 | $1.12M | 0.00% | +234,532+589.8% | Added |
| Morgan Stanley | 290,648 | $1.19M | 0.00% | −138,385−32.3% | Reduced |
| Laurion Capital Management LP | 300,000 | $1.22M | 0.02% | +300,000 | New |
| Vanguard Group Inc | 484,904 | $1.98M | 0.00% | +293,493+153.3% | Added |
| Rock Springs Capital Management LP | 829,102 | $3.38M | 0.07% | +829,102 | New |
| Lion Point Capital, LP | 833,333 | $3.40M | 0.90% | +833,333 | New |
| FMR LLC | 2,310,690 | $9.43M | 0.00% | −335,241−12.7% | Reduced |
| NEA Management Company, LLC | 4,017,170 | $16.4M | 0.21% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,386,568 | $17.9M | 0.20% | +1,666,666+61.3% | Added |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −248,804−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −193,904−100.0% | Sold out |
| Tibra Equities Europe Ltd | 0 | $0 | 0.00% | −37,500−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −31,546−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −18,284−100.0% | Sold out |
| Altfest L J & Co Inc | 0 | $0 | 0.00% | −15,234−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −13,794−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,143−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −116−100.0% | Sold out |